Showing 1641-1650 of 1849 results for "".
- The Election and The Marketshttps://practicaldermatology.com/news/the-election-and-the-markets/2458392/By David Mandell, JD, MBA and Robert Peelman, CFP® This presidential race is seemingly generating more interest, expressions of concern, and questions from clients than past elections. Some clients want to know how the election impacts our investment views and how we might ad
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- Syneron Receives FDA Clearance to Market the Ultrashape System for Fat Cell Destructionhttps://practicaldermatology.com/news/20140414-syneron_receives_fda_clearance_to_market_the_ultrashape_system_for_fat_cell_destruction/2459273/
- Veil Cosmetics Introduced to Markethttps://practicaldermatology.com/news/20120727-veil_cosmetics_introduced_to_market/2459761/The concept of makeup artist Sébastien Tardif, Veil Cosmetics was inspired by Tardif's foundation in both art and fashion, which inspired the palette of bright-based colors that lift and illuminate the skin. Tardif cultivated his skincare sensibilities during his tenure in Asia, which led him
- "Skin Rules" Hits Market March 13https://practicaldermatology.com/news/20120307-skin_rules_hits_market_march_13/2459854/Skin Rules (St. Martin's Press), a new book by dermatologist Debra Jaliman, MD, goes on sale March 13. According to a release, the book "lays out clear, easy-to-understand information on the latest technologies, such as Cool Sculpting (body co
- AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinibhttps://practicaldermatology.com/news/ad-vise-better-patient-outcomes-tied-to-achieving-mda-at-6-months/2486433/Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the r
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- Dr. Andrew Alexis Highlights 2-MNG as Option to Treat Acne-Related PIHhttps://practicaldermatology.com/news/dr-andrew-alexis-highlights-2-mng-as-option-to-treat-acne-related-pih/2483902/The topical agent 2-Mercaptonicotinoyl glycine (2-MNG), also marketed as Melasyl, could be key to treating acne-related postinflammatory hyperpigmentation (PIH) in skin of color, Andrew Alexis, MD, MPH, said at the Skin of Color Update in New York, New York. Dr. Alexis presented on managin
- Report: IL-17 Therapies Target PsO and More, Poised for Growthhttps://practicaldermatology.com/news/report-il-17-therapies-target-pso-and-more-poised-for-growth/2475920/The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report. Novel ag
- Nemolizumab Approved by European Commission for Moderate-to-severe Prurigo Nodularishttps://practicaldermatology.com/news/nemolizumab-approved-european-commission-for-moderate-to-severe-prurigo-nodularis/2471164/Nemolizumab has been approved by the European Commission for the treatment of moderate-to-severe prurigo nodularis, according to an announcement from Galderma. The approval of the monoclonal antibody (marketed as Nemluvio) fol